These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39412823)

  • 1. FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Kanapuru B; Zhao J; Price LSL; Zheng N; Konicki R; Manning ML; Gehrke BJ; Theoret MR; Gormley NJ
    Clin Cancer Res; 2024 Dec; 30(24):5515-5520. PubMed ID: 39412823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model.
    Willemin ME; Gong J; Hilder BW; Masterson T; Tolbert J; Renaud T; Heuck C; Kane C; De Zwart L; Girgis S; Ma X; Ouellet D
    Target Oncol; 2024 Nov; 19(6):965-979. PubMed ID: 39285155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
    Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
    Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
    Touzeau C; Krishnan AY; Moreau P; Perrot A; Usmani SZ; Manier S; Cavo M; Martinez Chamorro C; Nooka AK; Martin TG; Karlin L; Leleu X; Bahlis NJ; Besemer B; Pei L; Stein S; Wang Lin SX; Trancucci D; Verona RI; Girgis S; Miao X; Uhlar CM; Chastain K; Garfall AL
    Blood; 2024 Dec; 144(23):2375-2388. PubMed ID: 39172760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.
    Ishida T; Kuroda Y; Matsue K; Komeno T; Ishiguro T; Ishikawa J; Ito T; Kosugi H; Sunami K; Nishikawa K; Shibayama K; Aida K; Yamazaki H; Inagaki M; Kobayashi H; Iida S
    Int J Hematol; 2024 Nov; ():. PubMed ID: 39607603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.
    Cai Z; Xia Z; He AL; Dong YJ; Wang Y; Liao A; Song Y; Song Mm J; Uhlar C; Chastain K; Watkins L; Luo X; Huang L; Niu Z; Quijano Cardé NA; Guo Y; Xu H; Verona RI; Zhou L; Li J; Fu W; Niu T; Du J
    Cancer; 2024 Dec; ():. PubMed ID: 39660861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
    Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
    Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
    Chowdary P; Angchaisuksiri P; Apte S; Astermark J; Benson G; Chan AKC; Jiménez Yuste V; Matsushita T; Høgh Nielsen AR; Sathar J; Sutton C; Šaulytė Trakymienė S; Tran H; Villarreal Martinez L; Wheeler AP; Windyga J; Young G; Thaung Zaw JJ; Eichler H
    Lancet Haematol; 2024 Dec; 11(12):e891-e904. PubMed ID: 39521008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma.
    Catamero D; Ray C; Purcell K; Leahey S; Esler E; Rogers S; Hefner K; O'Rourke L; Gray K; Tolbert J; Renaud T; Patel S; Hannemann L; Shenoy S
    Semin Oncol Nurs; 2024 Oct; 40(5):151712. PubMed ID: 39155155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.
    Gurumurthi A; Chin CK; Feng L; Fowler NH; Strati P; Hagemeister FB; Fayad LE; Westin JR; Obi C; Arafat J; Nair R; Steiner RE; Neelapu SS; Flowers CR; Nastoupil LJ
    EClinicalMedicine; 2024 Aug; 74():102747. PubMed ID: 39161543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for preventing weight gain after smoking cessation.
    Hartmann-Boyce J; Theodoulou A; Farley A; Hajek P; Lycett D; Jones LL; Kudlek L; Heath L; Hajizadeh A; Schenkels M; Aveyard P
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD006219. PubMed ID: 34611902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
    Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells.
    Supimon K; Sangsuwannukul T; Luangwattananun P; Yenchitsomanus PT
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113480. PubMed ID: 39467352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.
    Tang W; Li Y; Zhang L; Zhong X; Liang Q; Zheng Y; Liu Y; Wang Y; Wang X; Zeng Y; Fang B; Zheng L; Niu T
    Cancer Med; 2024 Jul; 13(14):e7435. PubMed ID: 39031941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
    Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
    Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.